Summary
Immunotherapy and chemotherapy before surgery show promise for stage 3 NSCLC patients, with 77% achieving two-year progression-free survival.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It is often diagnosed at a late stage, making treatment difficult. The study focused on patients with stage 3 NSCLC. These patients typically receive chemotherapy and radiation, but the cancer often returns.
This study looked at the effects of adding immunotherapy to the standard treatment. Immunotherapy helps the body’s own immune system fight cancer. Researchers found that patients who received immunotherapy and chemotherapy before surgery were more likely to live longer without the cancer coming back.
Specifically, 77% of patients who received the immunotherapy/chemotherapy combination were alive and cancer-free two years later. This is a significant improvement compared to previous treatments.
While these results are promising, more research is needed. Scientists want to confirm these findings in larger groups of patients. They also want to learn more about the long-term effects of this treatment combination. Still, this study offers a reason for optimism in the fight against lung cancer.
